MB-CART2019.1 is a type of advanced therapy that uses modified immune cells to target and destroy cancer cells. In this trial, it is being tested for its effectiveness and safety in treating patients with a specific type of lymphoma, known as relapsed or refractory diffuse large B-cell lymphoma (R-R DLBCL). This therapy is being compared to standard treatments to see if it can improve patient outcomes.

Rituximab is a medication that targets specific proteins on the surface of cancer cells, helping the immune system to destroy them. It is commonly used in combination with other drugs to treat certain types of lymphoma, including R-R DLBCL.

Gemcitabine is a chemotherapy drug that works by interfering with the DNA of cancer cells, preventing them from growing and dividing. It is often used in combination with other medications to treat various types of cancer, including lymphoma.

Oxaliplatin is another chemotherapy drug that damages the DNA of cancer cells, leading to their death. It is used in combination with other drugs to enhance the treatment of certain cancers, including lymphoma.

Relapsed/Refractory Diffuse Large B Cell Lymphoma (R-R DLBCL) – This is a type of non-Hodgkin lymphoma that affects B cells, which are a type of white blood cell. It is characterized by the return or persistence of the disease after initial treatment. The disease typically presents with rapidly growing lymph nodes, often in the neck, armpit, or groin. As it progresses, it can spread to other parts of the body, including the bone marrow, spleen, and liver. Symptoms may include fever, night sweats, and unexplained weight loss. The condition is considered rare and can be challenging to manage due to its aggressive nature.